Identification of the SOCS1 variant led to initiate ruxolitinib 10 mg twice daily, which resulted in spectacular improvement of intestinal symptoms as well as of arthritis, enabling steroids withdrawn. Here, SOCS1 is linked to arthritic joint disease.